The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss before noncontrolling interest | -151,612 |
| Depreciation and amortization | 6,575 |
| Equity-based compensation | 25,336 |
| Gain on marketable securities, net | 3,417 |
| Gain on lease disposition | 29 |
| Impairment charges | 318 |
| Loss on disposal of equipment | -1,431 |
| Interest receivable | -1,320 |
| Prepaid and other assets | -6,236 |
| Accounts payable and accrued expenses | -5,919 |
| Income taxes payable | -356 |
| Net cash flows used in operating activities | -120,117 |
| Proceeds from sale of facility | 18,215 |
| Purchases of marketable securities | 217,076 |
| Sales and maturities of marketable securities | 318,022 |
| Purchase of equipment and facility expansion | 15,196 |
| Net cash flows provided by (used in) investing activities | 103,965 |
| Proceeds from sales of class a ordinary shares, net of offering costs | 24,247 |
| Payments on finance leases | 26 |
| Exercise of stock options | 1,348 |
| Repurchase of class a common stock amount | 0 |
| Net cash flows provided by (used in) financing activities | 25,569 |
| Net change in cash and cash equivalents | 9,417 |
| Cash, beginning of period | 99,120 |
| Cash, end of period | 108,537 |
PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK)